Osteopetrosis clinical trials
The registry lists 22 studies for Osteopetrosis across 6 countries. 4 are recruiting or about to start. 12 of them are mainly about Osteopetrosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-03.
Get an email when these change. Save the Osteopetrosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Masonic Cancer Center, University of Minnesota (3) · Bellicum Pharmaceuticals (2) · Paul Szabolcs (2) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · St. Jude Children's Research Hospital (1) · Wake Forest University Health Sciences (1) · Kasr El Aini Hospital (1) · InterMune (1)
What is being tested here
Drugs under test in Osteopetrosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Fludarabine | 1 | 1 | 2 |
| Alemtuzumab | 1 | 0 | 2 |
| Hydroxyurea | 1 | 0 | 1 |
| Melphalan | 1 | 0 | 1 |
| Thiotepa | 1 | 0 | 1 |
| Rivogenlecleucel | 0 | 0 | 2 |
| Cyclophosphamide | 0 | 2 | 2 |
| Interferon gamma-1b | 0 | 0 | 2 |
| AP 1903 reagent | 0 | 0 | 1 |
| Thymoglobulin | 0 | 1 | 1 |
Drug classes tested here Alkylating agents 1 open · Antimetabolites 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Nov 2026Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT · Paul Szabolcs
Who these studies take
Of the 4 Osteopetrosis studies recruiting now, 1 (25%) set no upper age limit and 3 (75%) stop at 75 or younger. 4 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (75%) | 3 (75%) |
| 18 | 3 (75%) | 3 (75%) |
| 30 | 3 (75%) | 3 (75%) |
| 40 | 3 (75%) | 3 (75%) |
| 50 | 3 (75%) | 3 (75%) |
| 65 | 1 (25%) | 1 (25%) |
| 75 | 1 (25%) | 1 (25%) |
| 85 | 1 (25%) | 1 (25%) |
Across all 22 studies, recruiting or not: 68% stop at 75 or younger and 68% at 65; 91% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 22 of 22. search them.
- Gene-Modified Stem Cell Therapy for Children With Autosomal Recessive Osteopetrosis (ARO)RecruitingNCT07665021Phase 1/21 country
- Longitudinal Study of Neurodegenerative DisordersRecruitingNCT033332001 country
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICRecruitingNCT045283551 country
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 21 country
- MT2013-31: Allo HCT for Metabolic Disorders and Severe OsteopetrosisActive, not recruitingNCT02171104Phase 21 country
- Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant DiseasesCompletedNCT01019876Phase 2/31 country
- ACTIMMUNE in Intermediate OsteopetrosisCompletedNCT02666768Phase 21 country
- Outcomes of Patients With Osteopetrosis Weight-bearing Bone FracturesCompletedNCT06521580Not applicable1 country
- Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedNCT02065869Phase 1/22 countries
- Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell TransplantActive, not recruitingNCT03301168Phase 1/21 country
- T-cell Depleted Alternative Donor TransplantationTerminatedNCT00968864Phase 21 country
- Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell TransplantNo longer availableNCT012000171 country
- Use of ACTIMMUNE in Patients With ADO2CompletedNCT02584608Phase 21 country
- Allogeneic Transplantation For Severe OsteopetrosisCompletedNCT00775931Phase 2/31 country
- Reduced Intensity AlloTransplant For OsteopetrosisTerminatedNCT00638820Phase 21 country
- Stem Cell Transplantation for Children Affected With OsteopetrosisTerminatedNCT00145587Not applicable1 country
- Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood CellsCompletedNCT00730314Phase 1/21 country
- rhPTH Therapy for Low Turnover Bone FragilityTerminatedNCT00145886Phase 11 country
- Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital OsteopetrosisCompletedNCT00004402Phase 3
- Hematopoietic Stem Cell Transplantation for Malignant Infantile OsteopetrosisStatus unknownNCT01087398Phase 2/31 country
- Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5CompletedNCT011990941 country
- Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant OsteopetrosisCompletedNCT000433291 country